A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours

The aim of the study was to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and the pharmacokinetic profile (P(k)) of bendamustine (BM) on a day 1 and 2 every 3 weeks schedule and to recommend a safe phase II dose for further testing. Patients with solid tumours beyond...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasschaert, M, Schrijvers, D, Van den Brande, J, Dyck, J, Bosmans, J, Merkle, K, Vermorken, J B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359912/
https://www.ncbi.nlm.nih.gov/pubmed/17486132
http://dx.doi.org/10.1038/sj.bjc.6603776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359912/
https://www.ncbi.nlm.nih.gov/pubmed/17486132
http://dx.doi.org/10.1038/sj.bjc.6603776

Ejemplares similares